Glenmark Pharmaceuticals Wins Right to Sell HIV Diarrhea Drug in 140 Countries

An international arbitrator ruled that India's Glenmark Pharmaceuticals has the right to sell its HIV-associated diarrhoea drug Crofelemer in 140 countries. Glenmark developed Crofelemer with U.S.-based partners Napo Pharmaceuticals and Salix Pharmaceuticals Ltd. The Indian company sought arbitration in the United States last December after Napo terminated a three-party agreement under which Glenmark holds the exclusive right to distribute Crofelemer in 140 countries including India. Salix was to sell the drug in regulated markets such as North America, Japan and Europe.